These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31054767)

  • 1. Relevance of neuroendocrine tumours models assessed by kinomic profiling.
    Romano D
    Ann Endocrinol (Paris); 2019 Jun; 80(3):144-148. PubMed ID: 31054767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
    Scarpa A
    Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
    Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
    Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging clinical relevance of genomic profiling in neuroendocrine tumours.
    Burak GI; Ozge S; Cem M; Gulgun B; Zeynep DY; Atil B
    BMC Cancer; 2021 Mar; 21(1):234. PubMed ID: 33676450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours.
    Samsom KG; Levy S; van Veenendaal LM; Roepman P; Kodach LL; Steeghs N; Valk GD; Wouter Dercksen M; Kuhlmann KFD; Verbeek WHM; Meijer GA; Tesselaar MET; van den Berg JG
    Histopathology; 2021 Mar; 78(4):556-566. PubMed ID: 32931025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets.
    Park HY; Kwon MJ; Kang HS; Kim YJ; Kim NY; Kim MJ; Min KW; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Lee HK
    Hum Pathol; 2019 May; 87():83-94. PubMed ID: 30851333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium.
    Mafficini A; Scarpa A
    J Endocrinol; 2018 Mar; 236(3):R161-R167. PubMed ID: 29321190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites.
    Pareja F; Vahdatinia M; Marchio C; Lee SSK; Da Cruz Paula A; Derakhshan F; da Silva EM; Selenica P; Dopeso H; Chandarlapaty S; Wen HY; Vincent-Salomon A; Brogi E; Weigelt B; Reis-Filho JS
    J Clin Pathol; 2022 Jan; 75(1):10-17. PubMed ID: 33148628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinome rewiring during acquired drug resistance in neuroendocrine neoplasms.
    Gérard C; Lagarde M; Poizat F; Oziel-Taieb S; Garcia V; Roche C; Niccoli P; Barlier A; Romano D
    Endocr Relat Cancer; 2021 Jan; 28(1):39-51. PubMed ID: 33112824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.
    Capdevila J; Meeker A; García-Carbonero R; Pietras K; Astudillo A; Casanovas O; Scarpa A
    Cancer Metastasis Rev; 2014 Mar; 33(1):345-51. PubMed ID: 24375391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of new candidate genes and signalling pathways associated with the development of neuroendocrine pancreatic tumours based on next generation sequencing data.
    Kit OI; Trifanov VS; Petrusenko NA; Gvaldin DY; Kutilin DS; Timoshkina NN
    Mol Biol Rep; 2020 Jun; 47(6):4233-4243. PubMed ID: 32451928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour biology of gastroenteropancreatic neuroendocrine tumours.
    Grötzinger C
    Neuroendocrinology; 2004; 80 Suppl 1():8-11. PubMed ID: 15477708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.
    Pipinikas CP; Berner AM; Sposito T; Thirlwell C
    Endocr Relat Cancer; 2019 Aug; 26(9):R519-R544. PubMed ID: 31252410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches.
    Oberg K; Casanovas O; Castaño JP; Chung D; Delle Fave G; Denèfle P; Harris P; Khan MS; Kulke MH; Scarpa A; Tang LH; Wiedenmann B
    Clin Cancer Res; 2013 Jun; 19(11):2842-9. PubMed ID: 23459719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis in neuroendocrine tumours.
    Wang DG
    Clin Endocrinol (Oxf); 1999 Jul; 51(1):1-9. PubMed ID: 10468958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?
    Raymond E; García-Carbonero R; Wiedenmann B; Grande E; Pavel M
    Cancer Metastasis Rev; 2014 Mar; 33(1):367-72. PubMed ID: 24375390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Entrectinib in a Patient With the First Reported
    Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.